[HTML][HTML] Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin

M Brom, W Woliner-Van Der Weg, L Joosten, C Frielink… - Diabetologia, 2014 - Springer
… Maarten Brom, Wietske Woliner-van der Weg, Lieke Joosten, Cathelijne … Wietske Woliner-van
der Weg … Maarten Brom and Wietske Woliner-van der Weg contributed equally to this …

Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer

R Schoffelen, W Woliner-van der Weg… - European journal of …, 2014 - Springer
Purpose Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies (bsMAb) and a
radiolabeled peptide reduces the radiation dose to normal tissues. Here we report the …

Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients

…, I van der Kroon, W Woliner-van der Weg… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Being highly expressed in insulinomas, the glucagonlike peptide-1 receptor (GLP-1R) is a
potential target for diagnosis, localization, and treatment with the radiolabeled GLP-1R …

[HTML][HTML] A 3D-printed anatomical pancreas and kidney phantom for optimizing SPECT/CT reconstruction settings in beta cell imaging using 111In-exendin

W Woliner-van der Weg, LN Deden, APW Meeuwis… - EJNMMI physics, 2016 - Springer
Background Quantitative single photon emission computed tomography (SPECT) is challenging,
especially for pancreatic beta cell imaging with 111 In-exendin due to high uptake in …

[HTML][HTML] Noninvasive skin barrier assessment: multiparametric approach and pilot study

JGM Logger, JI Olydam, W Woliner-van der Weg… - Cosmetics, 2019 - mdpi.com
The epidermal barrier function is disrupted in various inflammatory skin diseases. Accurate
methods to measure skin barrier function are needed to assess the effect of therapeutic …

[HTML][HTML] Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy

W Woliner-van der Weg, R Schoffelen, RF Hobbs… - EJNMMI physics, 2015 - Springer
Background Red bone marrow (RBM) toxicity is dose-limiting in (pretargeted) radioimmunotherapy
(RIT). Previous blood-based and two-dimensional (2D) image-based methods have …

[HTML][HTML] Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendin

I Van Der Kroon, W Woliner-van der Weg, M Brom… - Scientific Reports, 2017 - nature.com
Radiolabeled exendin is used for non-invasive quantification of beta cells in the islets of
Langerhans in vivo. High accumulation of radiolabeled exendin in the islets raised concerns …

PS18-2. Quantification of the beta cell mass based on 111In-Exendin imaging in patients with type 1 diabetes and healthy controls

W Woliner-van der Weg, M Brom, MJR Janssen… - Nederlands Tijdschrift …, 2013 - Springer
Various tests exist to quantify beta cell (BC) function, but do not necessarily provide
information on BC mass (BCM), while BCM seems an important predictor of future BC failure. A …

[BOOK][B] Clinical application of quantitative SPECT in patient specific dosimetry and beta cell quantification

W Woliner-van der Weg - 2015 - research.utwente.nl
Wietske Wolinervan der WegWietske Wolinervan der Weg geboren op 27 maart
1987 te Leeuwarden … Woliner-van der Weg, 2015 …

[PDF][PDF] Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendin

I Kroon, W Woliner-van der Weg, M Brom, L Joosten… - 2017 - repository.ubn.ru.nl
Radiolabeled exendin is used for non-invasive quantification of beta cells in the islets of
Langerhans in vivo. High accumulation of radiolabeled exendin in the islets raised concerns …